Donna Weber is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 435 publications with 12,361 citations (h-index 36); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 6 Jul 2012.
Clinical trials
- Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center
- Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
Sponsor: M.D. Anderson Cancer Center
- Thalidomide for Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
82.3%Thalidomide Analog70.6%Revlimid44%Lenalidomide33%Pomalyst23%Part D≥17 patientsBCL-2 Inhibitor11.7%Venclexta100%Part D<11 patientsSensory organs
10.4%Corticosteroid10.4%Dexamethasone100%Part D≥17 patientsAnti-infectives
7.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor7.4%Valacyclovir100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2014 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Journal of the National Comprehensive Cancer Network
2022 - Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2020 - NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
Journal of the National Comprehensive Cancer Network
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”